Long-term Tolerance to Islet Transplantation via Targeted Reduction of beta cell-specific T cells

Area of Science:

• Immunology
• Endocrinology
• Cell Biology

Background:

• Type 1 diabetes (T1D) is an autoimmune disease characterized by the destruction of pancreatic beta cells, leading to insulin insufficiency.
• Current treatments, primarily exogenous insulin, manage symptoms but do not offer a cure.
• Islet transplantation is a potential curative approach, but graft acceptance is hindered by autoimmune T cell attacks and the need for immunosuppression.

Purpose of the Study:

• To investigate a novel therapeutic strategy for achieving long-term acceptance of islet grafts in T1D.
• To target and eliminate autoreactive T effector cells responsible for islet destruction.
• To assess the efficacy of a combination therapy in preventing graft rejection and restoring normoglycemia.

Main Methods:

• Utilized the NOD mouse model of T1D.
• Administered a short-acting combination therapy, termed 'p53 potentiation with checkpoint abrogation' (PPCA), targeting DNA damage response pathways in T effector cells.
• Analyzed T cell subsets, including CD4+, CD8+, and regulatory T cells (Tregs), using single-cell RNA-seq and assessed graft acceptance and glycemic control.

Main Results:

• PPCA therapy effectively eliminated activated beta-cell-reactive CD4+ and CD8+ T effector cells by inducing apoptosis via DNA damage response.
• The therapy preserved T regulatory cells, crucial for immune tolerance.
• In established diabetic NOD mice, a single course of PPCA resulted in long-term acceptance of autologous islet grafts, restoration of normoglycemia, and a reduction in islet-specific T cells.

Conclusions:

• Targeted elimination of autoreactive T effector cells using PPCA is a viable strategy for achieving islet graft tolerance in T1D.
• This approach holds promise for enabling islet transplantation without the need for prolonged immunosuppression.
• PPCA therapy represents a potential breakthrough for the curative treatment of Type 1 diabetes.